Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 1.90 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AcelRX Pharmaceuticals Inc | ACRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.08 | -4.04% | 1.90 | 2.00 | 1.90 | 2.00 | 1.98 | 00:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.85 | 2.05 | 0.20 | 9.76% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,285 | 687,168 | $ 1.94 | $ 1,334,118 | 1,028,324 | 1.64 - 4.09 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:55:38 | 99 | $ 1.90 | USD |
AcelRX Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 151.19M | 79.57M | $ -47.15M | -0.81 | - | 77.58M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 9.00 | 2.50% |
AcelRX Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.99 | 2.10 | 1.83 | 1.95 | 737,886 | -0.09 | -4.52% |
| 1 Month | 2.17 | 2.44 | 1.83 | 2.10 | 864,421 | -0.27 | -12.44% |
| 3 Months | 2.18 | 2.50 | 1.64 | 2.01 | 1,048,886 | -0.28 | -12.84% |
| 6 Months | 2.77 | 2.86 | 1.64 | 2.18 | 888,627 | -0.87 | -31.41% |
| 1 Year | 2.36 | 4.09 | 1.64 | 2.80 | 1,383,754 | -0.46 | -19.49% |
| 3 Years | 2.80 | 5.75 | 1.55 | 3.10 | 1,289,457 | -0.90 | -32.14% |
| 5 Years | 7.00 | 9.32 | 1.55 | 3.27 | 946,124 | -5.10 | -72.86% |
AcelRX Pharmaceuticals Description
| AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. |
